Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
It is also approved for?AIDS-related Kaposi sarcoma?after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma
Vinita has made expansion in the U.S. a core pillar of Lupin’s worldwide growth strategy
Nadda underlined that India’s policy framework is aligned with this transformation
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
